Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 19 | 2024 | 931 | 3.380 |
Why?
|
| Peritoneal Dialysis | 9 | 2024 | 140 | 2.530 |
Why?
|
| Renal Dialysis | 14 | 2024 | 903 | 1.570 |
Why?
|
| Catheters, Indwelling | 4 | 2024 | 382 | 1.150 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 713 | 1.060 |
Why?
|
| Catheter-Related Infections | 6 | 2024 | 274 | 0.960 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 2 | 2020 | 24 | 0.860 |
Why?
|
| Hydrothorax | 1 | 2020 | 18 | 0.710 |
Why?
|
| Calcimimetic Agents | 1 | 2019 | 5 | 0.690 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2019 | 19 | 0.690 |
Why?
|
| Kidney Transplantation | 4 | 2023 | 750 | 0.510 |
Why?
|
| Renal Insufficiency | 4 | 2024 | 304 | 0.480 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2019 | 55 | 0.470 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2014 | 89 | 0.440 |
Why?
|
| Latent Tuberculosis | 1 | 2014 | 86 | 0.440 |
Why?
|
| Child | 26 | 2024 | 30560 | 0.410 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 101 | 0.360 |
Why?
|
| Renal Replacement Therapy | 3 | 2023 | 149 | 0.330 |
Why?
|
| Vesico-Ureteral Reflux | 2 | 2023 | 88 | 0.330 |
Why?
|
| Nephrosis, Lipoid | 1 | 2009 | 12 | 0.330 |
Why?
|
| Nephrotic Syndrome | 1 | 2009 | 54 | 0.320 |
Why?
|
| Catheterization | 3 | 2022 | 416 | 0.310 |
Why?
|
| Cost Savings | 1 | 2008 | 124 | 0.300 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 350 | 0.290 |
Why?
|
| Infant | 11 | 2024 | 13994 | 0.280 |
Why?
|
| Ascitic Fluid | 2 | 2017 | 84 | 0.280 |
Why?
|
| Oxygen | 2 | 2021 | 786 | 0.270 |
Why?
|
| Child, Preschool | 12 | 2024 | 17072 | 0.260 |
Why?
|
| Hypertension | 2 | 2019 | 1584 | 0.240 |
Why?
|
| Peritonitis | 2 | 2024 | 98 | 0.240 |
Why?
|
| Acute Kidney Injury | 2 | 2024 | 758 | 0.230 |
Why?
|
| Adolescent | 17 | 2024 | 32689 | 0.220 |
Why?
|
| Health Care Costs | 1 | 2008 | 696 | 0.220 |
Why?
|
| Pruritus | 1 | 2023 | 92 | 0.210 |
Why?
|
| Oximetry | 2 | 2021 | 190 | 0.200 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 41 | 0.200 |
Why?
|
| Observer Variation | 1 | 2024 | 709 | 0.200 |
Why?
|
| Humans | 35 | 2024 | 270713 | 0.200 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 141 | 0.190 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 100 | 0.190 |
Why?
|
| Brain Chemistry | 1 | 2021 | 165 | 0.190 |
Why?
|
| Kidney | 3 | 2023 | 2102 | 0.190 |
Why?
|
| Ureter | 1 | 2023 | 218 | 0.180 |
Why?
|
| Hematocrit | 1 | 2020 | 149 | 0.170 |
Why?
|
| Retrospective Studies | 12 | 2023 | 39959 | 0.170 |
Why?
|
| Blood | 1 | 2020 | 162 | 0.170 |
Why?
|
| Standard of Care | 2 | 2019 | 277 | 0.170 |
Why?
|
| Veins | 1 | 2020 | 161 | 0.170 |
Why?
|
| Infant Formula | 1 | 2020 | 98 | 0.170 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2020 | 211 | 0.160 |
Why?
|
| Male | 21 | 2024 | 128479 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 112 | 0.150 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 494 | 0.150 |
Why?
|
| Arterial Pressure | 1 | 2019 | 106 | 0.150 |
Why?
|
| Infant, Newborn | 7 | 2024 | 8603 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 143 | 0.150 |
Why?
|
| Creatinine | 1 | 2020 | 525 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 193 | 0.150 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2017 | 10 | 0.150 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 79 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 402 | 0.150 |
Why?
|
| Sevelamer | 1 | 2017 | 10 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 347 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 563 | 0.150 |
Why?
|
| Hyperphosphatemia | 1 | 2017 | 20 | 0.150 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 122 | 0.150 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 19 | 0.150 |
Why?
|
| Milk, Human | 1 | 2020 | 306 | 0.140 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 380 | 0.140 |
Why?
|
| Chylous Ascites | 1 | 2017 | 24 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2019 | 626 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2021 | 380 | 0.140 |
Why?
|
| Chelating Agents | 1 | 2017 | 131 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 588 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 363 | 0.140 |
Why?
|
| Bacteremia | 1 | 2022 | 722 | 0.140 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 176 | 0.130 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 153 | 0.130 |
Why?
|
| Peritoneum | 1 | 2016 | 151 | 0.120 |
Why?
|
| Female | 16 | 2024 | 148885 | 0.120 |
Why?
|
| Heart | 1 | 2021 | 1173 | 0.120 |
Why?
|
| Nephrology | 1 | 2016 | 153 | 0.120 |
Why?
|
| Skin Tests | 1 | 2014 | 100 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2019 | 912 | 0.110 |
Why?
|
| Urogenital Abnormalities | 1 | 2016 | 174 | 0.110 |
Why?
|
| Sepsis | 1 | 2019 | 673 | 0.110 |
Why?
|
| Texas | 3 | 2017 | 6446 | 0.110 |
Why?
|
| Hyperammonemia | 1 | 2013 | 65 | 0.100 |
Why?
|
| Risk Factors | 4 | 2018 | 17861 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 871 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 473 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2023 | 33847 | 0.090 |
Why?
|
| Pediatrics | 2 | 2019 | 1195 | 0.090 |
Why?
|
| Quality of Life | 2 | 2023 | 4810 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 899 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1576 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2014 | 679 | 0.080 |
Why?
|
| Transplant Recipients | 2 | 2022 | 335 | 0.080 |
Why?
|
| Glomerular Mesangium | 1 | 2009 | 36 | 0.080 |
Why?
|
| Young Adult | 5 | 2019 | 22243 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 113 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2009 | 293 | 0.070 |
Why?
|
| Incidence | 1 | 2018 | 5825 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 311 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 886 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 1117 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 982 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2009 | 9463 | 0.070 |
Why?
|
| Age Factors | 3 | 2021 | 5441 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 966 | 0.060 |
Why?
|
| Hospitals, Pediatric | 1 | 2008 | 796 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4394 | 0.050 |
Why?
|
| Nitrogen | 1 | 2024 | 174 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 15275 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5777 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 1436 | 0.050 |
Why?
|
| Hypoxia, Brain | 1 | 2021 | 36 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 322 | 0.050 |
Why?
|
| Adult | 3 | 2023 | 82041 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2024 | 350 | 0.050 |
Why?
|
| Living Donors | 1 | 2022 | 170 | 0.050 |
Why?
|
| Biopsy | 1 | 2009 | 3490 | 0.050 |
Why?
|
| Blood Volume | 1 | 2021 | 105 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2021 | 192 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 3245 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 4007 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 4494 | 0.050 |
Why?
|
| United States | 1 | 2018 | 15828 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2020 | 105 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 42 | 0.040 |
Why?
|
| Renal Veins | 1 | 2019 | 63 | 0.040 |
Why?
|
| Iliac Vein | 1 | 2019 | 41 | 0.040 |
Why?
|
| Vascular Grafting | 1 | 2019 | 46 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 550 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 49 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 96 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 100 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 1076 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 509 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2022 | 844 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 370 | 0.040 |
Why?
|
| Iohexol | 1 | 2017 | 56 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 288 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 666 | 0.040 |
Why?
|
| Nephrology Nursing | 1 | 2016 | 2 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2017 | 69 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2021 | 941 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 686 | 0.040 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 37 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 602 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 41 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2024 | 13419 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 180 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2020 | 476 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 189 | 0.030 |
Why?
|
| Myocardium | 1 | 2021 | 1180 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 2051 | 0.030 |
Why?
|
| Echocardiography | 1 | 2021 | 1219 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 666 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 419 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 734 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 610 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 1246 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 1065 | 0.030 |
Why?
|
| Thrombosis | 1 | 2019 | 742 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4966 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 2040 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 762 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2016 | 2315 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2016 | 824 | 0.020 |
Why?
|
| Body Weight | 1 | 2016 | 1287 | 0.020 |
Why?
|
| Reoperation | 1 | 2016 | 1389 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1301 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 1276 | 0.020 |
Why?
|
| Contrast Media | 1 | 2017 | 1505 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 819 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2395 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 5048 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1716 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4838 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 1302 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3435 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4644 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5674 | 0.010 |
Why?
|